Hainan Shuangcheng Buys Hangzhou Ausia Biotech Stake For $154 Million

February 4, 2015 -- Hainan Shuangcheng Pharma will acquire a 56% stake in Hangzhou Ausia BioTech at a price of $154 million. Shuangcheng will raise $144 million in a private placement to pay for the acquisition. Hangzhou Ausia is a contract manufacturer specializing in aseptic manufacturing of lyophilized (freeze-dried) vials. In 2014, Ausia recorded operating income of $36.7 million and $15 million of net profit